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Abstract
Background: Computer tomography (CT) is still the fastest and most robust technique to rule out ICH in acute
stroke. However CT-sensitivity for detection of ischemic stroke in the hyperacute phase is still relatively low.
Moreover the validity of pure clinical judgment is diminished by several stroke imitating diseases (mimics). The
“Triage
® Stroke Panel”, a biochemical multimarker assay, detects Brain Natriuretic Peptide (BNP), D-Dimers (DD),
Matrix-Metalloproteinase-9 (MMP-9), and S100B protein and promptly generates a Multimarkerindex of these values
(MMX). This index has been licensed for diagnostic purposes as it might increase the validity of the clinical
diagnosis to differentiate between stroke imitating diseases and true ischemic strokes. Our aim was to prove
whether the panel is a reliable indicating device for the diagnosis of ischemic stroke in a time window of 6 h to
fasten the pre- and intrahospital pathway to fibrinolysis.
Methods: We investigated all consecutive patients admitted to our stroke unit during a time period of 5 months.
Only patients with clinical investigation, blood sample collection and MRI within six hours from symptom onset
were included. Values of biochemical markers were analyzed according to the results of diffusion weighted MR-
imaging. In addition MMX-values in ischemic strokes were correlated with the TOAST-criteria. For statistical analysis
the SAS Analyst software was used. Correlation coefficients were analyzed and comparison tests for two or more
groups were performed. Statistical significance was assumed in case of p < 0.05. Finally a ROC-analysis was
performed for the MMX-Index.
Results: In total 174 patients were included into this study (n = 100 strokes, n = 49 mimics, n = 25 transitoric
ischemic attacks). In patients with ischemic strokes the mean NIHSS was 7.6 ± 6.2, while the mean DWI-lesion
volume was 20.6 ml (range 186.9 to 4.2 ml). According to the MMX or the individual markers there was no
statistically significant difference between the group of ischemic strokes and the group of mimics. Moreover the
correlation of the index and the DWI-lesion-volume was poor (p = 0.2).
Conclusions: In our setting of acute MRI-proven ischemic stroke the used multimarker-assay (Triage
® Stroke Panel) was
not of diagnostic validity. We do not recommend to perform this assay as this might lead to a unjustified time delay.
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Background
Stroke represents the 2nd leading cause of death and the
most common cause of morbidity in industrialized
countries. Although systemic fibrinolysis has been pro-
ven to be an effective therapy even in industrialized
countries only the minority of all ischemic stroke
patients receives rtPA therapy [1,2]. Therefore, acute
stroke therapy remains one of the essential challenges of
Neurology. In case of acute stroke it’s important to
apply immediately reliable diagnostic tools to start treat-
ment as soon as possible as the time to recanalization is
a very substantial predictor of the clinical outcome [3].
Acute stroke-imaging is still predominantly based on
CT although detection of ischemic lesions at this time
point is often difficult as early ischemic signs are only
present in one third to one half of the cases [4]. Even
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any medium, provided the original work is properly cited.with sophisticated procedures like perfusion CT it is not
possible to yield a higher sensitivity especially in case of
non-territorial infarctions [5]. In contrast MRI provides
a very high sensitivity and specificity for detection of
ischemic strokes even in the hyperacute stage [6-8].
However a comprehensive availability of MRI has not
been achieved yet. Thus the diagnosis of ischemic stroke
in most cases is still based on clinical estimation after
ruling out intracerebral hemorrhage (ICH) by CT. How-
ever several other diseases like seizures or migraine
make the correct diagnosis difficult. To enhance the
clinical sensitivity and specificity several investigations
on biochemical markers were performed. According to a
significant increase of markers of inflammation, throm-
bosis and cellular death as well as myelin damage within
24 h from stroke onset a point-of-care immunoassay
(Triage Stroke Panel
®) has been developed. This system
rapidly analyses Brain Natriuretic peptide (BNP), D-
Dimers (DD), Matrix Metalloproteinase-9 (MMP-9) and
S 100 B protein to estimate-together with a Multimar-
kerindex (MMX)-the probability of stroke. The aim of
our investigation was to prove, whether this panel could
enhance the diagnostic reliability and differentiate
between ischemic stroke patients and patients with
stroke imitating diseases (mimics).
Methods
All patients consecutively admitted over a time period of
5 months to the stroke unit of the University Hospital of
Ulm with the tentative diagnosis of an acute stroke were
investigated. Patients were only included into the study
if they were admitted in a maximum time frame of 6 h
from symptom onset. Clinical investigation and collec-
tion of blood samples were performed immediately after
admission. This procedure was directly followed by a
typical standard MRI-based stroke imaging protocol
(DWI, T2*w, TOF-MRA, FLAIR, T2w, T1w, PWI).
Patients who did not receive a MRI, e.g. due to contra-
indications to magnetic resonance imaging or for techni-
cal reasons were not included.
Finally patients were divided into three groups: group
I consisted of ischemic stroke patients according to the
judgment of the treating neurologist confirmed by a
typical DWI-lesion. This group included also patients
that were clinically classified as transitoric ischemic
attack (TIA), but demonstrated an acute DWI-lesion
correlating with the neurological deficit. In the absence
of a typical DWI-lesion these patients were categorized
in the classical way as TIA and included in group II. All
other patients were included into the group III with
patients with stroke imitating diseases (mimics).
In group I the volume of the ischemic lesions was
measured by determining the DWI-lesion size using an
in-house developed volumetric software (TIFT). The
analysis of the biochemical markers (BNP, D-Dimers,
MMP-9, S 100 B, MMX) was done by Sandwich-Fluor-
escence-Immunoassay-Technology of the so-called
Triage
® Stroke Panel using blood from an EDTA sample
taken within 15 min after admission. All stroke patients
got the generally performed diagnostic investigations
including sonography of the extracranial and intracranial
arteries, ECG, long-term ECG and transthoracal echo-
cardiography. Transoesophageal echocardiography was
performed on an individual base. The TOAST classifica-
tion was used to define the stroke etiology [9]. Clinically
the severity of the neurological deficit was assessed
using the National Institute of Health Stroke Scale
(NIHSS). Clinical development was evaluated by com-
paring the baseline NIHSS score ad admission with a
repeated investigation measured 7 days after stroke or at
discharge from the stroke unit. Statistics were performed
by the SAS Analyst software. General characterization of
patients was done by a descriptive analysis. The specifi-
tity and sensitivity of the MMX as well as of the single
parameters of the panel were calculated by comparing
the results between group I and III performing a ROC
-Analysis. To rule out any uncertainty we excluded the
TIA group from this analysis. In addition the results of
the biochemical markers in the stroke group were corre-
lated with the size of the respective acute DWI-restric-
tions in the MRI. For the correlation analysis Spearman
correlation coefficients (p) and scatter plots were used.
For pointing out differences between groups we per-
formed the Fisher exact test (2 variables) and c
2-test (>
2 variables) for non-continuous variables and the Wil-
coxon- (2 variables) and Kruskal-Wallis-Test (> 2 vari-
ables) for continuous variables. Statistical significance
was assumed in case of p < 0.05. Finally a ROC-analysis
was performed for the MMX-Index.
The ethics committee of the University of ULM
approved the study. Written informed consent was
obtained by all included patients or their legal guardian.
Results
In total 174 patients were included. The cohort con-
sisted of 100 ischemic stroke patients (group I) with a
median age of 73 years (range 18-97 years), 25 patients
with TIAs (group II) with a median age of 74 years
(range 40-88 years) and 49 mimics patients (group III)
with a median age of 65 years (range 22-93 years).
Demographic as well as clinical characteristics of
patients are shown in Table 1. Beside a higher incidence
of atrial fibrillation in the group of ischemic stroke
patients there were no significant differences between
the three groups in terms of demographic characteristics
and vascular risk factors.
Admission after the first symptoms was within 1 h in
9% of the patients, between 1 h and 3 h in 56% and
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admission time was 3.03 ± 1.74 h after the first symp-
toms. Patients in the mimics group were suffering from
migraine with aura (n = 4), other types of headache (n =
3), seizures with concomitant postictual paresis (n = 12),
dizziness (n = 7), syncopes (n = 8), hypertensive ence-
phalopathy (n = 1), idiopathic paresis of the facial nerve
(n = 1), transient global amnesia (n = 2) and other diag-
nosis (n = 11). According to the TOAST-criteria 35% of
t h ei s c h e m i cs t r o k ep a t i e n t ss u f f e r e df r o mc a r d i o -
embolic strokes, 39% from stroke of thrombembolic ori-
gin and only 3% were judged to have microangiopathic
strokes. In 4% other, rare causes of stroke have been
found, while in 19% the origin of the stroke remained
unclear or was possibly due to more than one single
cause. 76% of the ischemic strokes were localized in the
anterior circulation territory (70% in MCA territory)
and 23% in the vertebrobasilar territory (10% in PCA
territory, 10% in the brain stem, 10% in the PICA terri-
tory). We quantified the acute lesion size by an in-house
developed software measuring the acute DWI-lesion size
on admission, which means immediately after collecting
the blood sample for the biochemical analysis. The
mean lesion size was 20.6 ml ranging from 4.2 to 186.9
ml. Clinically the mean NIHSS was 6 (median; range 0-
2 5 )a ta d m i s s i o na n d4( m e d i a n ;r a n g e0 - 1 9 )a td i s -
charge. There was a significant correlation of the
ischemic lesion size and the clinical presentation of
s t r o k e so na d m i s s i o na sw e l la s7d a y sl a t e r( o ra td i s -
charge) (Spearman’s p = 0.57 and p = 0.47 respectively).
The triage stroke panel measures BNP, DD, MMP-9,
S100 B and generates the Multimarkerindex of these
values (MMX). In our investigation this index did not
differ statistically significantly between the both groups
of mimics and strokes (mean 4.2 ± 1.7 vs. 3.6 ± 2.0, n.
s.). Moreover not even a modest correlation was found
between the DWI-lesion size and the MMX-value (p =
0 . 2 ,s e eF i g u r e1 :C o m p a r i s o no ft h eD W I - l e s i o ns i z e
and the MMX-values. No significant correlation was
obtained). According the time window from symptom
onset MMX did not differ statistically significant
between a time frame of 3 h and 6 h from symptom
onset (median 4,5 and 4,6; n.s.).
The two most reasonable MMX cut-offs (2.3 and 2.5)
which we could derive from our own dataset reached
indeed sensitivities of 86% and 84%. However, the corre-
sponding specificities were only 33% and 35%. For the
officially recommended cut-offs at 1.3 and 5.9 we
obtained either a high sensitivity of 92% with a low spe-
cificity of 14% or a good specificity of 86% and a poor
sensitivity of 14% respectively. In general no cut-off
value with a clinically useful sensitivity and specificity
could be found (see Table 2)
Consequently the ROC analysis for MMX showed a
low discriminatory power with an AUC-value of 0.59
(see Figure 2: ROC-Analysis of the MMX-Value with a
poor AUC-Value of 0,59).
Similar results were obtained, when we performed sta-
tistical analysis on the correlation of the individual mar-
kers of the panel and the DWI-lesion-size. In our group
nearly 98% (n = 170) of the patients did not reach the
lower limit of the testing range for S100 B. Thus no sta-
tistics were performed for this individual item. For
MMP-9 and D-Dimers no statistically significant differ-
ences were obtained between the two groups of mimics
and strokes. Only measuring BNP-levels led to a signifi-
cant difference between these both groups (median 64.5
in strokes vs. 19.3 in mimics p = 0,01, see Table 3)
Further subgroup analysis yielded a strong significant
trend (p = 0,002) with higher BNP-values in case of car-
dioembolic stroke according to the TOAST classification
compared to other stroke etiologies (median 131 vs.
19,8). When we excluded patients with a supposed car-
diogenic etiology from the stroke group, the difference
between the other TOAST-groups to the mimics in
terms of BNP did not longer stay significant. In addi-
tion, we didn’t find a strong correlation with the DWI-
lesion volume neither for the BNP-values nor for any
other biochemical marker (p = 0,09, see Figure 3: Com-
parison of the DWI-lesion size and the BNP-values. No
significant correlation was obtained).
Discussion
An early and valid diagnosis expedites the way to
fibrinolysis in ischemic stroke and excludes stroke
imitating diseases from the potentially dangerous ther-
apeutic intervention. To improve the reliability of the
clinical diagnosis the Triage
® Stroke Panel has been
developed. A recent investigation proved whether this
multimarker assay could increase the diagnostic sensi-
tivity of a clinical prehospital stroke scale in-between
the first 24 h after the initial symptoms [10]. We
wanted to prove the diagnostic sensitivity and specifi-
city of this test solely in the therapeutically relevant
Table 1 Demographic characteristics and vascular risk
factors
Strokes TIAs Mimics p-value
Numers (n) 100 25 49
Age (years): median (range) 73 (18;97) 74 (40;88) 65 (22;93) 0.13
Gender: no of males (%) 52 (52) 11 (44) 27 (55) 0.62
Hypertension: n (%) 76 (76) 21 (84) 31 (63) 0.11
Diabetes: n (%) 32 (32) 5 (20) 9 (18) 0.15
Smokers: n (%) 14 (14) 5 (20) 6 (12) 0.66
Dyslipidemia: n (%) 44 (44) 13 (52) 14 (29) 0.09
Atrial fibrillation: n (%) 35 (35) 3 (12) 7 (14) 0.006*
Knauer et al. BMC Neurology 2012, 12:14
http://www.biomedcentral.com/1471-2377/12/14
Page 3 of 7time window up to six hours. To exclude any clinical
uncertainty we compared the biomarker index as well
as its individual parameters with the MRI results of
ischemic stroke patients and stroke imitating diseases.
In case of acute DWI-lesions patients clinically rated
as TIAs were classified as ischemic strokes according
to their greater risk of recurrent cerebrovascular
events [11]. The group of TIA patients without DWI-
lesions was not included in the statistical calculation
of sensitivity and specificity in order to rule out any
diagnostic uncertainty. Furthermore to avoid any
selection bias patients were included consequently
after the admission to our hospital. The group of
ischemic strokes consisted of a quite common spec-
trum of older patients with typical stroke patterns, e.g.
stroke of the anterior circulation of mostly throm-
boembolic origin. The only demographic difference
was a higher proportion of patients with atrial fibrilla-
tion in the group of ischemic strokes compared to the
group of TIA’s and mimics. Consistently according to
the TOAST-criteria the treating physicians estimated
a percentage of cardiogenic strokes higher than usual,
while only a few strokes were judged as small vessel
disease. The latter is possibly due to the short time
window and the tendency to later admissions of lacu-
nar strokes with minor clinical deficits [12]. In con-
trast to earlier investigations [10,13,14] in our cohort
the multimarker-index or its individual items were not
able to differentiate between the groups of ischemic
strokes and mimics. This is possibly due to several
reasons. First in our cohort ischemic stroke was diag-
nosed according to a combination of the clinical judg-
ment and MR-imaging, which is clearly superior to a
diagnosis based on pure clinical judgment or on a
combination of clinical judgment and CT-imaging.
This is especially true in case of smaller ischemic
lesions with clinical syndromes that do not directly
Figure 1 Comparison of the DWI-lesion size and the MMX-values. No significant correlation was obtained.
Table 2 Diagnostic quality of MMX at different cut-off
values
MMX cut-off Sensitivity Specificity
1.3 92% 14%
2.3 86% 33%
2.5 84% 35%
5.9 15% 86%
7.3 5% 94%
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based on MRI we possibly included patients who
otherwise would not have been classified as ischemic
stroke. In contrast so called MRI-negative ischemic
strokes might led to the exclusion of patients which
would have been classified as ischemic stroke based
upon clinical judgment. However neither the imaging
parameters of our patients nor the clinical severity of
disease give rise to suchlike considerations. Both the
DWI-lesion size [15,16] as well as the mean NIHSS on
admission [10] were quite comparable to other investi-
gations. The one rather critical difference certainly is
the narrow time window, as we only included patients
up to 6 h after the onset of the first symptoms.
Although a lot of biomarkers have been shown to rise
after an ischemic stroke, most of them increase with a
considerably longer delay. While S 100 B seems to
peak after more than one day [17], MMP 9 seems to
rise within the first eight hours after stroke reaching
its maximum after 24 h [18]. This lag of time explains
the missing difference between the group of ischemic
strokes and stroke imitating diseases for S100 B and
MMP-9 in our cohort most likely. The solely marker
significantly heightened in the ischemic stroke popula-
tion compared to the mimics group at this early time
point was BNP. However this effect was caused by the
patients assumedly suffering from cardiogenic stroke.
These results are in concordance with several other
investigations, which demonstrated an augmented
expression of BNP predominantly in stroke of cardiac
origin [19,20], while other etiologies did not necessa-
rily demonstrate this elevation [21-23].
Figure 2 ROC-Analysis of the MMX-Value with a poor AUC-Value of 0,59.
Table 3 Median of the MMX and its individual Markers in
the stroke and mimics group.
Strokes Mimics Correlation to VDWI
Spearman’s r
Median Median P
MMX 4.6 3.5 0.07 0.2
BNP (ng/ml) 64.45 19.3 0.01* 0.09
D-Dimers
(ng/ml)
675 322 0.10 0.09
MMP 9 (ng/
ml)
78.9 101 0.66 0.06
In addition the correlation of these markers with the DWI-lesion size (VDWI) is
given
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gle parameters (or the MMX-value) and the ischemic
lesion size measured by the acute DWI-lesion volume.
Although there are several reports about shrinking DWI-
deficits, DWI-lesions at least approximately represent the
infarct core [24]. From a pathophysiological point of view
a biomarker for identifying ischemic strokes should
depend on the amount of irreversible damaged brain tis-
sue. One candidate marker indicating neuronal destruc-
tion would be NSE (Neuronspecific Enolase) [25,26].
As we missed to demonstrate a suchlike relationship
and the MMX Cut -off points reached only a weak and
clinically not reasonably sensitivity and specificity we
couldn’t demonstrate a general diagnostic value for the
investigated biochemical markers in our setting of
hyperacute ischemic stroke.
Conclusions
Neither one marker nor combination of all markers is of
significant benefit in acute stroke diagnostics. DWI-MRI
is still the procedure with the highest diagnostic quality
in case of acute cerebral ischemia. Nevertheless further
investigation of biochemical markers might lead to
higher diagnostic quality in acute stroke diagnosis, e.g.
in the differentiation of etiological subgroups.
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